Apollo Hospitals Enterprise Limited Q2FY26 Concall Decoded: Margins held, beds coming, Bangladesh sneezed—and Apollo barely blinked

1. Opening Hook

Just when investors were bracing for festival-season weakness, Bangladesh patient drop-offs, and new-hospital margin pain, Apollo calmly reported strong growth, stable margins, and expansion on schedule.

Q2 had dengue missing, Bangladesh wobbling, and costs front-loaded—yet Apollo still delivered. Management spoke with the confidence of a system that knows its cash engines are intact.

Occupancy dipped, ARPP jumped, EBITDA refused to crack, and expansion costs were politely parked in the future. If this was supposed to be a “soft quarter,” Apollo clearly didn’t get the memo.

Read on—because beneath the calm tone lies a hospital giant quietly preparing for its next growth cycle.

2. At a Glance

• Revenue ₹6,304 Cr (+13%) – Seasonal headwinds tried, Apollo shrugged.
• EBITDA ₹941 Cr (+15%) – Margins held steady despite hiring binge.
• PAT ₹910 Cr H1 (+33%) – Bottom line growing faster than beds.
• Hospital margin 24.6% – New beds didn’t dent the fortress.
• Occupancy 69% – Volumes dipped, realizations compensated.
• HealthCo EBITDA ₹110 Cr – Digital losses shrinking, finally behaving.

3. Management’s Key Commentary

“Healthcare Services margin remained robust at 24.6%.”
(Translation: Expansion costs tried hard, but failed. 😏)

“Medical admissions were lower due to seasonality.”
(Translation: Dengue didn’t show up this year, margins survived anyway.)

“ARPP grew 9% due to better clinical mix.”
(Translation: Fewer patients, but much more complicated—and profitable—ones.)

“Bangladesh had a 1% impact, 60% has already returned.”
(Translation: This was a speed bump, not a structural issue.)

“Six hospitals will be commissioned across Q3, Q4 and Q1.”
(Translation: Growth capex is now unavoidable. 😎)

“New hospitals EBITDA loss capped at ₹140–150 Cr.”
(Translation: Damage is known, controlled, and budgeted.)

4. Numbers Decoded